Shares of Tocagen Inc (NASDAQ:TOCA) have been given an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Analysts have set a twelve-month consensus price target of $23.67 for the company, according to Zacks. Zacks has also given Tocagen an industry rank of 111 out of 265 based on the ratings given to its competitors.
Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday. Stifel Nicolaus reiterated a “buy” rating and set a $24.00 target price on shares of Tocagen in a research report on Tuesday, July 25th.
Tocagen (NASDAQ:TOCA) last announced its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. equities analysts forecast that Tocagen will post -2.88 EPS for the current year.
A number of large investors have recently bought and sold shares of the stock. Granahan Investment Management Inc. MA bought a new stake in Tocagen during the 3rd quarter valued at $392,000. BBR Partners LLC bought a new stake in Tocagen during the 3rd quarter valued at $181,000. JPMorgan Chase & Co. raised its holdings in Tocagen by 52.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock valued at $7,886,000 after buying an additional 218,100 shares during the last quarter. California State Teachers Retirement System bought a new stake in Tocagen during the 2nd quarter valued at $179,000. Finally, EcoR1 Capital LLC bought a new stake in Tocagen during the 2nd quarter valued at $18,074,000. Institutional investors own 37.88% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/11/18/zacks-tocagen-inc-toca-given-23-67-average-price-target-by-analysts.html.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.